Latest News and Press Releases

                Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...

Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...

PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...

Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...

               Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...

              Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...

New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- According to the market.us, the anticipated value of the Global Regenerative Medicine Market is projected to reach approximately USD 194.9 billion by the...

Wilmington, Delaware, United States, June 19, 2023 (GLOBE NEWSWIRE) -- In 2022, the global cell therapy technologies market was estimated to be worth $14.9 billion USD. It is expected to grow at a...

Seattle, WA, May 18, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced it will...

Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...